trending Market Intelligence /marketintelligence/en/news-insights/trending/xnezzlpvxg9jvd_3exdpew2 content esgSubNav
In This List

Trillium Therapeutics director retires

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Trillium Therapeutics director retires

Trillium Therapeutics Inc. said Henry Friesen retired as a board member in May.

The company, which develops therapies to treat cancer, named Friesen as director emeritus.

Friesen had been serving as a director at the company for the last seven years.